{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nFor example, HR2 peptides, as exemplified by DP178 (also known as T20, enfuvirtide, and Fuzeon\u00ae; SEQ ID NO:2), T651 (SEQ ID NO:3), T649 (SEQ ID NO:4), blocked infection of target cells with potencies of 0.5 ng/ml (EC50 against HIV-1<sub>LAI</sub>), 5 ng/ml (IC50; HIV-1 IIIB), and 2 ng/ml (IC50; HIV-1 IIIB), respectively."}
{"final_json": [{"molecule_name": "DP178", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": "2", "binding_metric": "EC50", "value": "0.5", "unit": "ng/ml"}, {"molecule_name": "T651", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": "3", "binding_metric": "IC50", "value": "5", "unit": "ng/ml"}, {"molecule_name": "T649", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": "4", "binding_metric": "IC50", "value": "2", "unit": "ng/ml"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nPeptides tested for antiviral activity were diluted into various concentrations, and tested in duplicate or triplicate against an HIV inoculum adjusted to yield approximately 1500-2000 infected cells/well of a 48 well microtiter plate, and then the IC50 was calculated (expressed in \u03bcg/ml).\nThe IC50 is defined as the concentration of active ingredient resulting in a 50% reduction in infectious virus titer)."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": "\u03bcg/ml"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": null}]}
